Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Above 50 Day Moving Average – Here’s Why

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$9.29 and traded as high as C$9.57. Fennec Pharmaceuticals shares last traded at C$9.57, with a volume of 5,399 shares changing hands.

Fennec Pharmaceuticals Stock Performance

The firm has a 50 day moving average of C$9.29 and a two-hundred day moving average of C$8.00. The stock has a market cap of C$184.55 million, a P/E ratio of -162.11 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total value of C$87,552.00. Insiders sold a total of 21,186 shares of company stock worth $196,017 in the last 90 days. 16.20% of the stock is owned by company insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.